Boston Scientific Corp.

Marlborough-based medical device manufacturer Boston Scientific has reached an agreement to acquire Xlumena Inc. Based in Mountain View, Calif., Xlumena makes minimally invasive devices to drain targeted areas of the gastrointestinal tract through endoscopic ultrasound. The deal is valued at $75 million and was expected to close this week, Boston Scientific (BSX) said in a statement Wednesday afternoon.

Boston Scientific of Marlborough has won federal regulatory approval for an implantable medical device that helps patients at high risk for stroke, the company said.

At the end of 2005, Boston Scientific Corp. made the fateful choice to buy cardiovascular equipment company Guidant Corp. for $27 billion. Since then, repercussions from the acquisition have weighed on the Marlborough-based medical device company. But with the settlement of a lawsuit over the deal in February, the company seems to be moving forward.

Boston Scientific has agreed to acquire the urology division of American Medical Systems for about $1.6 billion in cash, the Marlborough-based life sciences company announced Monday morning.

Boston Scientific has agreed to pay rival Johnson & Johnson $600 million as part of a settlement of a lawsuit stemming from Boston Scientific's acquisition of Guidant Corp. nine years ago, the Marlborough life sciences company announced Tuesday. In the lawsuit, Johnson & Johnson alleged that Guidant broke a deal it had with Johnson & Johnson to merge with that firm, and sought $7.2 billion in damages. Guidant disputed the allegations. As part of the settlement, BSX said Johnson & Johnson has agreed to dismiss its lawsuit without acknowledgment of liability by Guidant. Also, BSX has agreed not to bring patent infringement or other claims related to three of Johnson & Johnson's stent products, the BSX statement said.

Boston Scientific Corp. (NYSE: BSX) of Marlborough saw sales improve in the fourth quarter and throughout 2014, thanks in large part to strong sales of the company's cardiovascular devices.

Boston Scientific of Marlborough suffered a rough month in the legal system in November after two federal court juries awarded more than $45 million to eight women who claimed injuries from the medical device manufacturer's transvaginal mesh devices. What do they mean for the company?

Amid the controversy over national health care reform, the Affordable Care Act has raised serious hackles with the medical device tax, especially in Massachusetts. Now, with Republicans set to control both chambers of Congress in January, it looks like a repeal of the tax may be in the works.

Several major companies with operations in Central Massachusetts received the highest scores on equality from a national advocacy group for lesbian, gay, bisexual, and transgender (LGBT) Americans.

Marlborough-based Boston Scientific Corp. (NYSE: BSX) saw revenue climb 6 percent over 2013 in the third quarter, driven largely by sales of its cardiovascular products, according to an earnings statement released Tuesday. Net sales for the company totaled $1.8 billion in the quarter ended Sept. 30, up from $1.7 billion a year earlier. Earnings per share increased to 3 cents, compared with less than a penny per share a year earlier, on net income of $43 million. That's a turnaround from a net loss of $5 million in the third quarter of 2013.